

Special Issue

Novel Therapeutic Approaches for Colorectal Cancer

Message from the Guest Editors

Colorectal cancer (CRC) is the third most common cancer worldwide, with a 5-year survival rate (all stages) of 64%. Early-stage, non-metastatic CRC is primarily managed surgically, followed by adjuvant systemic chemotherapy or radiotherapy, while the first-line treatment for metastatic CRC usually involves systemic chemotherapy with capecitabine, irinotecan, oxaliplatin, and 5-fluorouracil, alone or in combination with biologics or immunotherapeutic drugs. However, the onset of multidrug-resistant mechanisms and severe side effects and the poor quality of life induced by these treatments have prompted the development of novel and potentially more effective therapeutic options for CRC treatment. This Special Issue aims to collect original research articles and comprehensive reviews on the most recent advances concerning CRC treatment, including (but not limited to) the following: novel small anticancer molecules; epigenetic drugs; nanotechnology-based combination therapies; targeted therapies including external-stimuli-activated approaches; drug repurposing; immunotherapeutic approaches. We look forward to receiving your contributions.

Guest Editors

Dr. Marzia Bruna Gariboldi

Dr. Greta Varchi

Dr. Claudia Ferroni

Deadline for manuscript submissions

closed (31 July 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/140951

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)